(Publ. 17 MAY 2018) The Swedish biopharmaceutical company BioArctic has been awarded the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by contributing to societal benefit emphasizing the importance of a successful life science industry in Sweden. BioArctic is awarded the prize, among other things, for their innovative projects for treatment of Alzheimer’s and Parkinson’s, as well as their successful stock market introduction earlier this year.

BioArctic is a Swedish research-based biopharmaceutical company that develops antibody-based disease modifying treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company also develops an innovative treatment concept for complete spinal cord injuries.

“It is a great honor for BioArctic to receive this award. It is gratifying and inspiring for us all at BioArctic. We are proud of our successes. The award is a confirmation of BioArctic’s contributions to the continued positive development of the Swedish life science industry,” says Gunilla Osswald, CEO of BioArctic in a press release.

It is twelfth consecutive year that SwedenBIO Award is awarded. The former winners are Oncopeptides, Alligator Bioscience, Recipharm, Orexo, Affibody, Vitrolife, Aerocrine, BioInvent, Cellavision, Medivir and Gyros.

You can read more about our patent advisory services in connection with BioArctic’s IPO here: Patent advice regarding an IPO for Life Science company

We would like to extend our warmest congratulations to BioArctic!